This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revision | Next revisionBoth sides next revision | ||
home:othertreatments:chemotherapy [11.13.2011] – [Rituximab] paulalbert | home:othertreatments:chemotherapy [11.13.2011] – [Rituximab] paulalbert | ||
---|---|---|---|
Line 43: | Line 43: | ||
- | In 2011, a Norwegian study published in //PLoS One// studied the effect of Rituximab – a monoclonal antibody otherwise used in cancers and anti-rejection treatment for organ transplants – on patients with CFS. In the 25-week study period, fatigue improved significantly in 10 out of 15 patients versus 2 out of 15 controls.(({{pubmed> | + | In 2011, a Norwegian study published in //PLoS One// studied the effect of Rituximab – a monoclonal antibody otherwise used in cancers and anti-rejection treatment for organ transplants – on patients with chronic fatigue syndrome. In the 25-week study period, fatigue improved significantly in 10 out of 15 patients versus 2 out of 15 controls.(({{pubmed> |
===== Patient interviews | ===== Patient interviews |